Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

N Engl J Med. 2011 May 12;364(19):1788-90. doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13.

Authors

B Nhi Beasley¹, Ellis F Unger, Robert Temple

Affiliation

¹ Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21488759
DOI: 10.1056/NEJMp1103050

No abstract available

MeSH terms

Anticoagulants / administration & dosage*
Anticoagulants / adverse effects
Atrial Fibrillation / drug therapy*
Benzimidazoles / administration & dosage*
Benzimidazoles / adverse effects
Dabigatran
Drug Approval*
Embolism / prevention & control*
Hemorrhage / chemically induced
Humans
Stroke / prevention & control*
Therapeutic Equivalency
United States
United States Food and Drug Administration
Warfarin / adverse effects
Warfarin / therapeutic use
beta-Alanine / administration & dosage
beta-Alanine / adverse effects
beta-Alanine / analogs & derivatives*

Substances

Anticoagulants
Benzimidazoles
beta-Alanine
Warfarin
Dabigatran